CION Ameerpet
Pediatric Cancer — Parent’s Guide
Relapsed neuroblastoma — options & support
Medically reviewed by Dr. Naresh Gundu, DM (Medical Oncology) · Last reviewed June 2026
If your child’s neuroblastoma has come back or has not responded to initial treatment, you are facing one of the hardest moments any family can encounter. This page explains, in plain language, what neuroblastoma relapse and refractory neuroblastoma mean, how they are confirmed, and what the realistic treatment pathways look like. Every decision at CION is made by a full tumour board — never by a single doctor.
- Free second opinion — written, based on your child’s actual reports and imaging
- Tumour board review — medical, surgical, and radiation specialists together
- 45-minute consultation — no rushed decisions; every question is heard
- Transparent costs — written plan and cost estimate before anything starts
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Understanding the diagnosis
What does neuroblastoma coming back actually mean?
Neuroblastoma is a cancer of the developing nervous system, most commonly seen in young children. Many children with neuroblastoma respond to treatment. For some, however, the disease returns after an initial period of remission — this is called a neuroblastoma relapse. For others, the tumour does not respond adequately to treatment even from the start; this is called refractory neuroblastoma.
Both situations share a common reality: the tumour has shown that it can persist despite treatment. This does not mean nothing further can be done. It means the care team needs to reassess the full picture — where the disease has spread, what its current biology looks like, and which treatment approaches the tumour has not yet encountered.
Neuroblastoma can return in the original site, in the lymph nodes, in the bone or bone marrow, or in other organs. Where it returns, and how extensively, shapes the treatment options the tumour board will discuss. The biology of the relapsed tumour — particularly features like MYCN amplification and tumour histology — is reassessed at relapse because it can change, and this matters for treatment planning.
The most important thing to understand at this stage is that no single doctor should be making the treatment decision for a child with relapsed neuroblastoma. This is a situation that requires the collective judgment of a multi-disciplinary tumour board — and it is entirely reasonable to seek a second opinion to ensure that all available options have been considered.
Three patterns the tumour board looks for
Understanding the pattern of how neuroblastoma has returned helps the team decide which approach is most appropriate for your child.
Most common
Local or regional relapse
The tumour regrows in or near the original site, or in nearby lymph nodes. Imaging (MIBG scan, MRI, or CT) typically identifies this. Local relapse may offer different treatment options compared to widely spread disease, depending on the extent and the child’s overall situation.
Bone marrow involvement
Bone marrow relapse
Neuroblastoma cells return to the bone marrow, similar in some ways to leukaemia-like spread. Bone marrow biopsies are performed to confirm this. Bone marrow involvement affects which treatment combinations and consolidation approaches the tumour board will consider.
No prior remission
Refractory neuroblastoma
The tumour does not respond adequately to initial treatment — it persists or continues growing despite therapy. This pattern tells the team that the tumour has significant resistance to the approaches already used, and the next phase needs to account for this when selecting options.
Note: combinations of these patterns can occur. A full, complete assessment by a paediatric oncology tumour board is essential before any treatment decision is made.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Your child deserves a second opinion — before any decision is made.
We walk this journey with you — a 45-minute consultation, a full tumour board review, and a written plan of the options as we see them. No rushed decisions. No unnecessary tests.
What happens next
How relapsed neuroblastoma is assessed and managed — a parent’s walkthrough
This is not a rigid protocol — every child’s path is different. But understanding the general sequence helps you ask better questions and feel less out of control during an overwhelming time.
1
Re-staging — understanding exactly where the disease is now
Before any new treatment is started, the team needs to understand the current extent of disease. This means a fresh set of imaging studies — usually including an MIBG scan (because neuroblastoma cells typically absorb the MIBG tracer), CT or MRI scanning, and a bone marrow biopsy to check for marrow involvement. Urine and blood catecholamine levels are also measured. In many cases, a biopsy of the relapsed tumour is performed so that the team can check whether its molecular biology has changed since the original diagnosis. These tests are not repeated unnecessarily; each one gives information that directly shapes the treatment decision.
2
Tumour board review — no single doctor makes this decision
At CION Cancer Clinics, every relapsed childhood cancer case is reviewed by a full multi-disciplinary tumour board before any treatment recommendation is made. For relapsed neuroblastoma, this means medical oncologists, paediatric surgeons, radiation oncologists, and where relevant a nuclear medicine specialist all reviewing the child’s complete picture together. The board considers the re-staging results, the original tumour biology, what treatment has already been given, and what options remain. If your current centre is making these decisions with a single specialist or a small team, seeking a second opinion from a centre with a full tumour board is an important step.
3
Understanding the treatment options the board may discuss
Treatment for relapsed or refractory neuroblastoma is individualised; there is no single standard approach. Depending on your child’s specific situation, the tumour board may discuss systemic treatment combinations designed for relapsed disease, MIBG therapy (where radioactive material is directed to neuroblastoma cells that absorb the MIBG tracer), radiation therapy directed at specific disease sites, high-dose treatment with stem cell rescue, surgery to remove tumour deposits where feasible, or participation in a clinical trial evaluating newer approaches. Not all of these apply to every child. The board reviews which options are relevant to your child’s age, disease extent, prior treatment received, and current condition.
4
MIBG therapy — what it is and when it is considered
MIBG (metaiodobenzylguanidine) therapy is a treatment approach specific to neuroblastoma. It works because most neuroblastoma cells have a transport system that absorbs MIBG, and when this molecule is attached to a radioactive compound, it can deliver radiation directly to tumour cells throughout the body. MIBG therapy is considered when the neuroblastoma is confirmed to be MIBG-avid (meaning it absorbs the tracer on scan), and when systemic treatment alone is not providing adequate response. It is given in a specialist nuclear medicine setting. The tumour board will discuss whether MIBG therapy is relevant for your child based on their re-staging results and overall clinical picture.
5
Supportive care runs alongside every phase of treatment
Re-treatment for relapsed neuroblastoma is intensive, and the child’s overall wellbeing must be actively managed throughout every phase. This includes nutritional support to help the child tolerate treatment and maintain strength, management of treatment-related effects on blood counts and organ function, infection prevention during periods of low immunity, and psycho-oncology support for both the child and the wider family. At CION, these are coordinated from day one as part of the same integrated care plan — not referred elsewhere or left for the family to arrange. Our 17 super-specialist oncologists work alongside nutritionists and psycho-oncologists as one team.
6
You do not have to navigate this alone
When neuroblastoma comes back, the weight of uncertainty can feel impossible to carry. You are not alone in that — and you deserve honest, expert guidance that is led by what is right for your child, not by what is easiest or cheapest to offer. At CION, decisions are made for healing, not billing. Every recommendation goes through a tumour board. Costs are transparent and explained before you agree to anything. A free second opinion is available at any stage. We walk this journey with you — every step of the way, as long as it takes.
We walk this journey with you
You deserve an honest, expert second opinion.
A 45-minute consultation with our paediatric oncology team — your child’s full records reviewed, your questions answered, a written assessment of what we see as the options. No obligation. No rushed decisions.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Your questions about relapsed neuroblastoma — answered
What does it mean when neuroblastoma comes back after treatment?
When neuroblastoma returns after a period of remission, it is called a relapse. It means that some tumour cells survived the initial treatment and have started growing again — in the original site, in nearby lymph nodes, in the bone marrow, or in other parts of the body. When neuroblastoma does not respond adequately to treatment from the start (without achieving remission first), it is called refractory neuroblastoma. Both situations are different from the first diagnosis, and both require a fresh evaluation by a multi-disciplinary tumour board to determine the best path forward for your child.
How is relapsed neuroblastoma confirmed?
Confirming a neuroblastoma relapse involves several tests. Imaging — most commonly an MIBG scan, CT scan, or MRI — is used to identify where the tumour has returned. A bone marrow biopsy is usually performed to check whether leukaemia-like spread into the marrow has occurred. Blood and urine markers (catecholamines and their breakdown products) are measured, because neuroblastoma cells often produce these chemicals. In some cases, a biopsy of the relapsed tumour is taken to check whether its biology has changed compared to the original tumour, which can affect treatment choices.
What are the treatment options for relapsed or refractory neuroblastoma?
Treatment options for relapsed and refractory neuroblastoma are decided by a multi-disciplinary tumour board and depend on the child's age, the location and extent of disease, the biology of the tumour, and what treatment has already been given. Options discussed may include new systemic treatment combinations, MIBG therapy (where the tumour cells absorb a radioactive substance directed specifically at them), high-dose treatment with stem cell rescue, radiation directed at specific sites, and entry into clinical trials where novel approaches are being tested. No two children follow the same path; the tumour board reviews all of these factors together before any recommendation is made.
What is the difference between relapsed and refractory neuroblastoma?
Relapsed neuroblastoma means the disease had responded to treatment (achieving remission) and then came back. Refractory neuroblastoma means the disease did not respond adequately to initial treatment — it persisted or continued growing despite treatment. Clinically, both situations present a similar challenge: the tumour has shown that it can resist at least some standard approaches. The distinction matters because it helps the tumour board understand the disease's behaviour and plan the most appropriate next step. Both situations benefit from a second opinion at a centre that has experience with these complex cases.
Should we seek a second opinion for relapsed neuroblastoma?
A second opinion at this stage is not only reasonable — it is actively encouraged. Relapsed and refractory neuroblastoma is a complex situation where treatment options require careful, specialised judgment. Having an independent expert review your child's full records — including the original biopsy, prior treatment records, current imaging, and tumour biology — means the family can make decisions with greater confidence. At CION Cancer Clinics, we offer a free written second opinion for all childhood cancer patients. Our tumour board reviews the full picture and gives you a clear written assessment of the options as we see them.
What support is available for families when a child's neuroblastoma relapses?
When neuroblastoma comes back, the emotional weight on the entire family is enormous. Medical care is inseparable from emotional and practical support at this stage. At CION, every child's case is supported by a full care team that includes not just the oncologist but also a psycho-oncologist, a nutritional specialist, and a care coordinator who helps families navigate the system. You do not have to manage this journey alone — we walk every step of it with you. Our 45-minute consultations ensure your questions are heard and no decision is rushed.
Pediatric Cancer A–Z
Explore All Pediatric Cancer Topics
Browse our complete library of parent-facing guides, grouped by topic — from warning signs and cancer types to diagnosis, treatment, side-effect care, survivorship and family support.